Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of treatment persistence of acalabrutinib ± obinutuzumab in treatment-naive B-CLL
jRCT1071250076Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of acalabrutinib and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by AstraZeneca. Primary endpoint: Discontinuation-free survival at 2 years. Started Oct 2025; status: recruiting.
02
Drugs
acalabrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT1071250076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071250076.